Antidepressants are commonly supposed to enhance serotonergic and/or noradrenergic neurotransmission by inhibition of neurotransmitter reuptake through binding to the respective neurotransmitter transporters or through inhibition of the monoamine oxidase. Using the concentration-clamp technique and measurements of intracellular Ca 2 þ , we demonstrate that different classes of antidepressants act as functional antagonists at the human 5-HT 3A receptor stably expressed in HEK 293 cells and at endogenous 5-HT 3 receptors of rat hippocampal neurons and N1E-115 neuroblastoma cells. The tricyclic antidepressants desipramine, imipramine, and trimipramine, the serotonin reuptake inhibitor fluoxetine, the norepinephrine reuptake inhibitor reboxetine, and the noradrenergic and specific serotonergic antidepressant mirtazapine effectively reduced the serotonin-induced Na þ -and Ca 2 þ -currents in a dose-dependent fashion. This effect was voltage-independent and, with the exception of mirtazapine, noncompetitive. Desipramine, imipramine, trimipramine, and fluoxetine also accelerated receptor desensitization. Moclobemide and carbamazepine had no effect on the serotonin-induced cation current. By analyzing analogues of desipramine and carbamazepine, we found that a basic propylamine side chain increases the antagonistic potency of tricyclic compounds, whereas it is abolished by an uncharged carboxamide group. The antagonistic effects of antidepressants at the 5-HT 3 receptor did not correlate with their effects on membrane fluidity. In conclusion, structurally different types of antidepressants modulate the function of this ligand-gated ion channel. This may represent a yet unrecognized pharmacological principle of antidepressants.
Introduction
Inhibition of serotonin and/or noradrenaline reuptake or the inhibition of monoamine oxidase 1, 2 are mechanisms of action shared by most antidepressants. In addition, second messenger systems (cAMP), transcription factors such as the cAMP responsive element binding protein (CREB), 3 the brain-derived neurotrophic factor (BDNF), 3 and components of the hypothalamic-pituitary-adrenal system 4 have been identified as targets for antidepressants. In an attempt to reduce anticholinergic side effects, a major problem with tricyclic antidepressants, more specific compounds have been developed. These include selective serotonin reuptake inhibitors, for example, fluoxetine, selective norepinephrine reuptake inhibitors (SNARIs), for example, reboxetine, and noradrenergic and specific serotonergic antidepressants (NaSSAs) such as mirtazapine. 1, 2, 5, 6 Mirtazapine is an a 2 -antagonist and competitive inhibitor of serotonin type 2 (5-HT 2 ) and type 3 (5-HT 3 ) receptors. 1, 5 It is current belief that these new antidepressants, with the exception of mirtazapine, do not interact preferentially with neurotransmitter receptors. However, preliminary investigations suggested that also fluoxetine acts as a functional antagonist at 5-HT 3 receptors localized on neurons of rat nodose ganglia. 7 More recent electrophysiological data indicated that the antagonistic effect of fluoxetine is probably conferred by a noncompetitive mechanism of action. 8 The 5-HT 3 receptor constitutes a cation permeable ligand-gated ion channel that shares structural features with g-aminobutyric acid type A (GABA A ), glycine, and nicotinic acetylcholine (nACh) receptors. 9 Functional 5-HT 3 receptors exist either as homomeric 5-HT 3A receptors 9 or as heteromeric 5-HT 3AB receptors. 10, 11 Within the central nervous system, 5-HT 3 receptors are highly expressed in the area postrema, hippocampus, and the amygdala. 12, 13 Rapid excitatory neurotransmission mediated by 5-HT 3 receptors results in neurotransmitter release, especially of dopamine in mesolimbic pathways. 14 3 receptor antagonists prevent emesis induced by cytostatic drugs that are commonly employed in cancer therapy. [15] [16] [17] Moreover, based on animal models and preliminary clinical studies, it has been suggested that 5-HT 3 receptor antagonists display anxiolytic 18, 19 and atypical antipsychotic properties. [20] [21] [22] Ligand-gated ion channels such as 5-HT 3A receptors 23 or GABA A receptors 24, 25 are targets for modulation by neuroactive steroids, which is an important principle for the regulation of neuronal excitability. If such a modulation of neurotransmitter receptors is also achieved by antidepressants, this would challenge the concept of target specificity claimed so far for these drugs and might represent a not yet recognized principle of antidepressant drug action.
5-HT
In the present study, we show that different classes of antidepressants act as functional noncompetitive antagonists at the human 5-HT 3A receptor and at endogenous 5-HT 3 receptors of rat hippocampal neurons and of mouse neuroblastoma cells (N1E-115 cells). Moreover, we delineate characteristic structural components within these molecules that are necessary for this antagonistic action.
Materials and methods

Chemicals and drugs
The following compounds were used: serotonin (5-hydroxytrypamine, 5-HT) (Sigma, Deisenhofen, Germany), desipramine (RBI, Kö ln, Germany), imipramine (RBI), trimipramine (RBI), fluoxetine (Tocris, Kö ln, Germany), reboxetine (generous gift from Pharmacia & Upjohn, Kalamazoo, MI, USA), mirtazapine (generous gift from NV Organon, BH Oss, The Netherlands), moclobemide (generous gift from Roche, Grenzach, Germany), carbamazepine (RBI), 10,11-dihydrocarbamazepine (Aldrich, Taufkirchen, Germany), 10,11
]cyclohepten (dibenzosuberane; Aldrich). For stock solutions (10 mM), desipramine, imipramine, trimipramine, fluoxetine, and reboxetine were dissolved in aqua-bidest., all other compounds were dissolved in ethanol.
Cell culture
Human embryonic kidney cells (HEK 293 cells) stably expressing the human 5-HT 3A receptor (HEK-5-HT 3A cells) 26 were cultured in minimum essential medium (MEM; Gibco, Karlsruhe, Germany) supplemented with 10% fetal calf serum (FCS; Gibco), 1% glutamine, nonessential amino acids and antibiotics (Gibco) at 371C, 5% CO 2 , and 95% humidity.
For the preparation of primary hippocampal neurons, hippocampi were obtained from rat embryos (E20-E21) and transferred to Ca 2 þ -and Mg 2 þ -free Hank's-buffered salt solution (HBSS; Gibco, Karlsruhe, Germany) on ice. Cells were mechanically dissociated in 0.05% DNAase/0.3% ovomucoid (Sigma, Deisenhofen, Germany) following an 8 min preincubation with 0.66% trypsin/0.1% DNAase (Sigma). The dissociated cells were then centrifuged at 18 g for 10 min, resuspended in MEM (Gibco) and plated at a density of 150 000 cells cm À2 onto poly-DLornithine (Sigma)/laminin (Gibco)-precoated plastic Petri dishes (Peske, Aindling-Arnhofen, Germany). The cells were nourished with NaHCO 3 /HEPESbuffered MEM supplemented with 5% FCS and 5% horse serum (Gibco) and incubated at 371C with 5% CO 2 at 95% humidity. The medium was completely exchanged following inhibition of further glial mitosis with cytosine--D-arabinofuranoside (ARAC, 5 mM, Sigma) after about 5 days in vitro.
Mouse N1E-115 neuroblastoma cells were purchased from the European collection of cell cultures (ECACC, Salisbury, UK) and stored at À801C until further use. The cells were plated at a density of 100 000 cells cm À2 onto plastic Petri dishes, nourished with NaHCO 3 /HEPES-buffered MEM supplemented with 15% FCS (Gibco) and incubated at 371C with 5% CO 2 at 95% humidity. The medium was exchanged completely daily. Once every 3 days, cells were reseeded onto fresh Petri dishes following treatment with trypsin-EDTA (1% in phosphate-buffered saline, PBS), resuspension in MEM and centrifugation at 200 g for 4 min.
Preparation of purified plasma membranes HEK-5-HT 3A cells were harvested, washed twice with ice-cold PBS, and resuspended in homogenization buffer (20 mM HEPES, 5 mM EDTA, pH 7.4). The suspension was thoroughly homogenized and centrifuged at 40 000 g, 41C for 30 min. The pelleted crude membrane was resuspended in ice-cold homogenization buffer and further purified by sucrose density gradient centrifugation. For this purpose, 2 ml crude membrane preparation (approximately 10 mg protein) were layered on top of a gradient consisting of 3.5 ml of 60% (w/v) sucrose and 4 ml of 35% (w/v) sucrose prepared in homogenization buffer. After centrifugation at 11 500 g, 41C for 90 min (SW-41 rotor) the membranes at the upper 0-35% sucrose interface were collected and washed with homogenization buffer.
Electrophysiological recordings 5-HT-induced inward Na
þ -currents were recorded from lifted HEK-5-HT 3A and N1E-115 cells in the whole-cell voltage-clamp configuration as described previously. 23 In brief, short pulses of 5-HT (10 mM) were applied from a double-barreled application pipette moved by a piezo translator-driven device in the absence or presence of the respective drug at the indicated concentrations. 5-HT was applied in pulses of 2 s duration every 60 s. The respective drugs were diluted with bath solution (140 mM NaCl, 2.8 mM KCl, and 10 mM HEPES, pH 7.2) to the desired concentration. To control for any possible confounding solvent effects, cells were exposed to 0.1% ethanol in 5-HT-free or 5-HT-containing solutions. The currents were recorded at a holding potential of À50 mV (HEK-5-HT 3A ) or À70 mV (N1E-115) with an EPC-9 amplifier (Heka, Lamprecht, Germany) and analyzed using the Heka 8.5 PulseFit and IgorPro v.4.5 (Wavemetrics, Lake Oswego, OR, USA) software on a Power Macintosh G3 computer. Only results obtained from stable responses to 5-HT which showed at least 50% recovery after removal of the drugs entered the final analysis. When the recovery was o100% both control and recovery currents were considered assuming a linear time course for the rundown of the response.
Patch-clamp recordings (À70 mV) from hippocampal neurons were made after 12-15 days in vitro with polished glass electrodes (2-3 MO) in the whole cell mode at room temperature (20-221C) with the aid of an EPC-7 amplifier (List, World Precision Instruments, Berlin, Germany). Test substances were applied with a theta glass application system (15-20 ms exchange times). 7 cells per ml. Cells were loaded with fura2-AM (Calbiochem, Bad Soden, Germany) at a final concentration of 3 mM by incubation for 30 min at 371C in the dark. This mixture was diluted 10-fold with fresh HBSS and incubated for another 10 min at room temperature in the dark. To remove external dye the sample was centrifuged (300 g, 4 min) and resuspended in fresh HBSS to yield a final cell concentration of 10 7 cells per ml. [Ca 2 þ ] i was measured in cuvettes filled with 200 ml cell suspension and 1800 ml prewarmed HBSS (371C) using a fluorescence spectrometer LS50 (Perkin Elmer, Ü berlingen, Germany). 5-HT was applied 40 s after the recording onset (total recording time 2 min). The respective drug was added into the cuvette at the indicated concentrations and preincubated for 2 min. To control for any possible confounding solvent effects, [Ca 2 þ ] i was recorded at a constant ethanol concentration of 0.1% in the sample mixtures. Throughout the recording, the mixture in the cuvette was continuously stirred and kept at 371C. Digitonin (50 mM) and EGTA (10 mM) were used to obtain R max and R min . 27 
Binding of [
3 H]GR65630 to membrane fractions of cells expressing the 5-HT 3 receptor HEK-5-HT 3A cells of 10 confluent plates (+10 cm) were harvested, washed twice with PBS, and homogenized in 6 ml of 320 mM sucrose, 50 mM Tris-HCl, 1 mM EDTA, pH 7.5. After centrifugation at 750 g for 10 min, the supernatant was recentrifuged at 100 000 g for 45 min. The resulting pellet was resuspended in 4-6 ml assay buffer (50 mM Tris-HCl, 1 mM EDTA, pH 7.5). The preparation of membrane fractions was performed at 41C. For ligand-binding experiments, membrane fractions were incubated in microtiter plates in a total volume of 250 ml at 371C for 1 h with the indicated concentrations of [ Bound ligand was separated from free ligand by washing with ice-cold assay buffer and rapid filtration through Whatman GF/B filters with a Titertek cell harvester (Nunc, Wiesbaden, Germany). Radioactivity was determined by liquid scintillation spectroscopy. Nonspecific binding was determined in the presence of 10 mM MDL 72222. Specific binding represented 80-94% of the total binding. Binding data were analyzed with the EBDA and LIGAND programs, 28 which provide a nonlinear, least-squares regression analysis. Data are expressed as mean7SD of four independent experiments.
Measurement of steady-state anisotropy
Purified plasma membranes of HEK-5-HT 3A cells (50 mg of protein each) were resuspended in buffer (5 mM Tris, pH 7.0, 25 mM NaCl) and labeled with the fluorophore 1,6-diphenyl-1,3,5-hexatriene (DPH) at a final concentration of 0.3 mM. Test substances (10 ml from a 100-fold stock solution) were added to 1 ml of the plasma membrane suspension, and the steadystate measurements were performed after incubation for 1 h at 301C. For kinetic experiments, the membranes were incubated in a 1 ml cuvette at 301C for 3-5 min until a stable baseline fluorescence was obtained. Then, test compounds (10 ml) were added from a 100-fold stock solution, and changes in fluorescence were monitored online. The membrane suspension was mixed continuously by a magnetic stirrer. Fluorescence intensity and polarization measurements were performed in triplicate on a Quantamaster (PTI, Toronto, Canada) spectrofluorometer. The probe was excited at 362710 nm. Emission was measured at 430710 nm. A cutoff filter (GG 395) was placed in front of the emission filter to reduce light scattering. The steady-state fluorescence anisotropy, r, was determined as described previously. recordings were performed in the whole-cell configuration. The application of 5-HT (10 mM) via a fast application system elicited an inward current with a time to a peak (time constant of onset, t on ) of 25.874.2 ms and a peak amplitude of 0.5-3 nA. This application induced an incomplete receptor desensitization (time constant of desensitization t des ¼ 619754 ms). After the fast removal of 5-HT, the evoked current deactivated completely (time constant of offset t off ¼ 31387138 ms; n ¼ 30) (Figure 1a) . The concomitant application of 5 mM desipramine (DMI) markedly reduced the amplitude of the 5-HT-evoked current and accelerated its desensitization (Figure 1a ; see also Figure 4a , Table 1 ). The inhibitory effect of DMI on this 5-HT-evoked Na þ -current was most pronounced when DMI was present already concentrations within the low micromolar range markedly inhibited the 5-HT-evoked Na þ -peak current and the 5-HT-evoked [Ca 2 þ ] i peak. The amplitude of the plateau current measured at the termination of a 2 s application of 5-HT was more effectively reduced by DMI than the peak of this inward current (Figure 2b) . The dose-dependent decrease of the time constant for this desensitization suggests that DMI accelerates the desensitization of the 5-HT-evoked Na þ -current (Figure 2c ). DMI shared this antagonistic effect at the 5-HT 3A receptor with imipramine and trimipramine, two other structurally related tricyclic antidepressants (Figures 3 and 4b, c) , and antidepressants with different chemical structures ( Figure 3) and sites of action. Fluoxetine (Figure 4d ), a SSRI, reboxetine (Figure 4e ), a SNARI, as well as mirtazapine (Figure 4f ), a NaSSA and competitive antagonist at the 5-HT 3A receptor, inhibited both the 5-HT-evoked Na þ -current and the increase in [Ca 2 þ ] i in a dosedependent fashion ( Figure 5 ). These inhibitory effects of DMI, fluoxetine, and reboxetine on the 5-HT evoked Na þ -current were also observed both in primary cultures of rat hippocampal neurons and in N1E-115 cells that express endogenous 5-HT 3 receptors ( Figure 6 , Table 2 ).
In contrast, no antagonistic effect at the 5-HT 3A receptor was found with moclobemide ( Figure 4g ), a selective and reversible inhibitor of the monoamine oxidase type A (MAOI-A), and carbamazepine ( Figure  4h ), a mood stabilizing and anticonvulsant drug. Similar to DMI (Figure 2b) , imipramine, trimipramine, fluoxetine, and reboxetine exerted a more pronounced antagonistic effect on plateau currents than on peak currents (Table 1) . DMI, imipramine, trimipramine, and fluoxetine accelerated the desensitization kinetics of the 5-HT-evoked current ( Figure  4a -d, right panels); fluoxetine in addition accelerated whereas trimipramine slowed down the onset kinetics ( Table 1) . As shown for DMI (Figure 2c ), the effects of trimipramine and fluoxetine on the desensitization kinetics were dose-dependent (Table 1) . In contrast to the other antidepressants, mirtazapine displayed an about three-fold higher IC 50 value for plateau currents than for peak currents ( 1 mM) . Therefore, the antagonism of DMI, imipramine, trimipramine, fluoxetine, and reboxetine is mediated by a mechanism different from that achieved with competitive 5-HT 3A receptor antagonists.
Steady-state anisotropy of DPH-labeled purified plasma membranes from HEK-5-HT 3A cells was measured to detect eventual effects of different antidepressants on the physicochemical properties of the plasma membrane. DMI, imipramine, and fluoxetine (3-100 mM) decreased the anisotropy of the fluorescence probe DPH within seconds in a dosedependent fashion. At a 100 mM concentration Dr ¼ À0.0113 for DMI, À0.0069 for imipramine, and À0.0224 for fluoxetine. However, we found no correlation of the antidepressant-induced anisotropy changes and their antagonistic effect on the 5-HTevoked inward-current (coefficient r 2 ¼ 0.256). Solely fluoxetine elicited significant changes in anisotropy at concentrations less than 10 mM (eg at a 6 mM concentration Dr ¼ À0.0059). Mirtazapine, reboxetine, moclobemide, and carbamazepine did not change anisotropy values at concentrations below 100 mM (r ¼ 0.22370.009). Only at a concentration of 100 mM, mirtazapine (Dr ¼ À0.012) and reboxetine (Dr ¼ À0.007) caused a small decrease in anisotropy.
To identify structural components that are necessary to exert an antagonistic effect at the 5-HT 3A receptor, we tested the effects of various modified tricyclic compounds on the 5-HT-evoked Na þ -current and [Ca 2 þ ] i increase ( Figure 7 ). Like carbamazepine, 10,11-dihydrocarbamazepine had almost no inhibitory effect suggesting that the 10,11-double bond does not determine the antagonistic action on the 5-HT 3A receptor. Iminodibenzyl, the tricyclic core of DMI, inhibited the 5-HT-response much less than DMI (Figure 7) . Apparently, the existence of an N-bound propylamine side-chain is not a prerequisite for the antagonistic effect, but it enhances antagonistic actions. However, the antagonism of tricyclic compounds at the 5-HT 3A receptor is abolished by an Nbound carboxamide group. To investigate whether the nitrogen atom of the middle ring affects this antagonistic action, we tested the effect of dibenzosuberane on the 5-HT-evoked responses. Interestingly, dibenzosuberane, a tricyclic compound without a nitrogen Figure 3 Molecule structure of antidepressants.
Antagonism of antidepressants at the 5-HT 3 receptor B Eisensamer et al atom, had no effect on the Na þ -current (Figure 7 ), even at a concentration of 100 mM (peak current of 11079%, mean7SEM, n ¼ 4), but it markedly reduced the 5-HT-evoked increase in [Ca 2 þ ] i (Figure 7) .
Discussion
The present study shows that different classes of antidepressants act as functional antagonists at the human 5-HT 3A receptor stably expressed in HEK 293 cells and at endogenous 5-HT 3 receptors of rat hippocampal neurons and of mouse N1E-115 neuroblastoma cells. The tricyclic antidepressants DMI, imipramine, and trimipramine, which does not mainly inhibit serotonin or norepinephrine reuptake, the SSRI fluoxetine, the SNARI reboxetine, and the NaSSA mirtazapine antagonized 5-HT-evoked Na þ -and Ca 2 þ -peak currents at low micromolar concentrations (Figures 2, 5, and 6 ). In accordance with previous findings, mirtazapine displaced the selec- Table 1 ). Left panels represent the original traces. To delineate effects of the antidepressants on the kinetics of the 5-HT-evoked Na þ -current, the reduced peak amplitude was adjusted to the control peak (right panel). The upper bar indicates the application of 10 mM 5-HT, while the lower bar indicates the presence of the respective antidepressant at its IC 50 concentration. Moclobemide (g) and carbamazepine (h) were tested at a 10 mM concentration. Peak amplitudes were not adjusted to control peaks for moclobemide and carbamazepine because these compounds did not exert inhibitory effects on the 5-HT-evoked Na þ -current.
tive competitive 5-HT 3 receptor antagonist [ 3 H]GR65630 from the 5-HT-binding site. In line with such a competitive antagonistic action, the effect of mirtazapine is mainly reflected by the reduction of the peak current. In contrast, DMI, imipramine, trimipramine, fluoxetine, and reboxetine are noncompetitive antagonists with their most pronounced antagonistic effect on plateau rather than on peak currents ( Table 1 ). The effects of DMI (Figure 1b) , imipramine, trimipramine, fluoxetine, and reboxetine are voltage-independent, a finding that argues against an action as open-channel blockers at the 5-HT 3A receptor. This is also supported by the observation that already a pre-exposure of the receptor to these antidepressants reduced the 5-HT-evoked response (Figure 1a ), indicating that they did not need to access an open-channel pore to inhibit the ion flux. A functional antagonism at the 5-HT 3A receptor has been reported previously for imipramine 30 and fluoxetine. 7, 8, 30 The present study shows for the first time that these antidepressants are noncompetitive antagonists. In accordance with our results is a recent electrophysiological study that suggests that fluoxetine inhibits the 5-HT-evoked cation current in a noncompetitive manner. 8 The noncompetitive antagonistic action of reboxetine and trimipramine differs from that observed with the other antidepressants. Reboxetine and trimipramine apparently antagonized the 5-HTevoked cation current by an interaction with two sites of the 5-HT 3A receptor reflected by a Hill coefficient near À0.5, whereas DMI, imipramine, and fluoxetine yielded Hill coefficients of À0.72 to À1.08, suggesting an antagonism mediated by an interaction at a single site. Reboxetine had almost no effect on the kinetics of the 5-HT-evoked currents, while DMI, imipramine, and fluoxetine markedly decreased the time constant of receptor desensitization (Figure 4a -e, Table 1 ), which is compatible with a noncompetitive antagonistic action. 7, [30] [31] [32] Trimipramine decreased the time constant of receptor desensitization with low potency and slowed down onset kinetics (Table 1) .
In contrast to tricyclic antidepressants, fluoxetine, or reboxetine, neither the selective and reversible MAOI-A moclobemide nor the mood stabilizer and anticonvulsant carbamazepine were antagonists at the 5-HT 3A receptor (Figure 4g, h) . This difference between the tricyclic antidepressants and carbamazepine was attributed to the characteristics of their N-bound sidechains. Our results demonstrate that the antagonistic potency increases with a basic secondary/tertiary amine, while it disappears when a polar uncharged carboxamide group is introduced (Figure 7) . Conclusively, the lipophilic properties of a compound not merely determine its antagonistic action at the 5-HT 3A receptor as it has already been shown for steroids and aromatic alcohols. 23 In the present study, we demonstrate antagonistic effects of different types of antidepressants both on the 5-HT-evoked Na 10 Since Ca 2 þ is an important messenger for neurotransmitter release and postsynaptic signaling, the reduction of Ca 2 þ -influx by antidepressants may be involved in their effects on neuronal activity. 34 HEK 293 cells lack voltage-gated Ca 2 þ -channels. 35 Therefore, the 5-HT-evoked rise in [Ca 2 þ ] i can be attributed to Ca 2 þ -ions entering the cell through 5-HT 3A receptor channels. All antidepressants tested reduced both Na þ -and Ca 2 þ -currents, although to a different extent. Trimipramine and fluoxetine more effectively antagonized Ca 2 þ -fluxes, whereas reboxetine and mirtazapine were more effective in reducing Na þ -currents. This differential effect on Na þ -and Ca 2 þ -currents was also observed with dibenzosuberane, a DMI analogue, which markedly antagonized the 5-HT-evoked [Ca 2 þ ] i increase, but was without effect on Na þ -currents ( Figure 7 ). Thus, a tricyclic compound without a nitrogen atom differentially affects the permeability of the 5-HT 3A receptor for Na þ -and Ca 2 þ -ions. The permeability of nACh receptors for Na þ and Ca 2 þ has been shown to depend on the amino-acid sequence of a distinct channel region. Homomeric assemblies of nACha7 subunits lose their permeability for Ca 2 þ , but not for Na þ , when a glutamate residue within the channel pore is mutated to alanine. 36, 37 Within the corresponding region of the 5-HT 3 receptor, the 5-HT 3A subunit contains a glutamate residue, while the 5-HT 3B subunit has an alanine. Thus, the reduced content of anionic residues in the channel pore of the 5-HT 3B subunit has been assumed to be responsible for the reduced Ca 2 þ -permeability of the heteromeric 5-HT 3AB receptor. One possible hypothesis to explain the differential effects of distinct compounds on 5-HT-evoked Na þ -and Ca 2 þ -currents may be that some functional antagonists at the 5-HT 3 receptor modify the steric orientation of anionic residues within a critical pore region of the 5-HT 3 receptor.
To address the question whether the antagonistic effects of antidepressants at the 5-HT 3 receptor are related to their action on membrane fluidity, we assessed the effects of different classes of antidepressants on steady-state DPH fluorescence anisotropy of purified plasma membranes from HEK-5-HT 3A cells. Tricyclic antidepressants decreased the anisotropy values of HEK-5-HT 3A cells in the upper micromolar range, indicating an increase in membrane fluidity, as it has been observed in different membrane preparations from rat brains. 38, 39 In addition, spin-label studies suggested an increase in membrane fluidity after a treatment with DMI and imipramine at low micromolar concentrations. 40 However, in rat synap- Values (mean7SEM; n=3-4) indicate percent of the control current; ND=not determined.
Antagonism of antidepressants at the 5-HT 3 receptor B Eisensamer et al tosomal membranes, imipramine did not cause any appreciable changes in DPH fluorescence anisotropy even at concentrations up to 500 mM. 41 The present study shows that also fluoxetine, reboxetine, and mirtazapine decrease DPH fluorescence anisotropy in purified plasma membranes of HEK-5-HT 3A cells. However, with the exception of fluoxetine, which affected membrane anisotropy at low micromolar concentrations in a dose-dependent fashion, only concentrations far exceeding those required for a functional antagonistic effect at the 5-HT 3 receptor decreased membrane anisotropy. Moreover, there was no correlation between the effects of antidepressants on membrane anisotropy and their inhibition of the 5-HT-induced cation current. Thus, the inhibitory effects of antidepressants at this ligand-gated ion channel presumably are not merely mediated by their effects on membrane fluidity.
One hypothesis to explain the mechanisms underlying the action of noncompetitive antagonists at ligand-gated ion channels is the existence of an allosteric recognition site distinct from the agonist binding site. For the nACh receptor, photoaffinity labeling experiments revealed that steroids bind to residues located at the receptor-lipid interface and thus noncompetitively inhibit this ligand-gated ion channel. 42 Noncompetitive inhibition of the nACh receptor may also arise from interactions of insecticides and anesthetics with constituents of the receptor microenvironment. 43 Comparable investigations with 5-HT 3 receptors are lacking to date.
In conclusion, structurally different types of antidepressants are noncompetitive antagonists at the 5-HT 3A receptor. Since the concentrations necessary for an antagonistic action at this ligand-gated ion channel are reached both in animal studies 44, 45 and in neuroimaging studies in patients treated with fluoxetine, 46 ,47 the noncompetitive modulation of ligandgated ion channels such as the 5-HT 3 receptor challenges the concept of target specificity of new antidepressant compounds. Moreover, it may constitute a novel pharmacological principle of antidepressants. 
